 |
|
|
| |
ID Week
Oct 11-15 2023
Boston, MA
|
| |
| |
- HEPATITIS C VIRUS CARE CONTINUUM IN THE DIRECT- ACTING ANTIVIRAL ERA WITHIN THE US VETERANS HEALTH ADMINISTRATION - (10/26/23)
- Waning of Bivalent mRNA Vaccine Effectiveness
Against COVID-19-associated Hospitalization Among Adults -
IVY Network, 20 U.S. States,
September 8, 2022-May 31, 2023 - (10/26/23)
- Fully vaccinated individuals with immunocompromised conditions
are still at increased risk of severe COVID-19 outcomes from the
Omicron variant: initial results from INFORM, a retrospective health database observational study in England - (10/26/23)
- Use of Paxlovid for treatment of acute COVID-19 and occurrence of Post-COVID Conditions among adolescents and adults at high-risk for severe COVID-19, April 1 - December 31, 2022 - (10/26/23)
- A Systematic Literature Review Evaluating Real-World Use
of Nirmatrelvir-Ritonavir for the Prevention of COVID-19-Related
Hospitalization and Death - (10/26/23)
-
Molnupiravir and Nirmatrelvir/ritonavir effectiveness in reducing the risk for COVID-19 disease progression and death - (10/25/23)
- NIRMATRELVIR/RITONAVIR VERSUS PLACEBO IN UNVACCINATED AND VACCINATED HIGH-RISK PATIENTS - (10/25/23)
- Nirmatrelvir/ritonavir or Molnupiravir for Treatment of Non-hospitalized Patients with COVID-19 at Risk of Disease Progression - (10/25/23)
- Risk Factors for Seeking Medical Care Following Nirmatrelvir-Ritonavir (Paxlovid) Treatment For COVID-19 - (10/25/23)
- Drug-Drug Interaction Profiling of Obeldesivir, a Promising Oral Treatment for COVID-19 - (10/25/23)
-
High Death and Hospital Rates in US Group With HIV and Cirrhosis - Mark Mascolini (10/18/23)
-
Presence of mental health concerns is associated with poor
adherence in people taking pre-exposure prophylaxis in real-world
clinical practice in the United States - (10/18/23)
-
The First Ten Years of HIV Preexposure Prophylaxis
Use and Missed Opportunities at an Urban Academic Children's Hospital - (10/18/23)
- PEP-in-pocket (PIP): Long-term follow-up of on demand HIV post-exposure prophylaxis: Is PEP-in-Pocket Best Option for Low-Frequency High-Risk HIV Exposure? - Mark Mascolini (10/18/23)
-
Only Half Prescribed CAB PrEP Get at Least 1 Shot in US Outpatient Network - Mark Mascolini (10/18/23)
- Expanding PrEP by Embedding Navigators in High STI Testing Clinical Sites - (10/18/23)
- Racial and Sex PrEP Disparities Persist in US Veterans Study - (10/18/23)
- Consequences of Low-Level Viremia (undetectable-199) Among
Women with HIV in the United States: higher risk for viral failure & comorbidities - (10/17/23)
-
Pharmacist-Driven ART Start Cuts 37 Day Off Time From HIV Diagnosis to Undetectable - Mark Mascolini (10/17/23)
- HBV Screening and Vaccination Dropping in PrEP Users; Vaccinations Adherence - Mark Mascolini (10/17/23)
- Reasons Differ for Switch to DTG/3TC (Weight Concern)
and B/F/TAF (Adherence, Substance Abuse, Poor HIV Control) - Mark Mascolini (10/17/23)
- A Quality Improvement Initiative for HIV Prevention in Underserved Communities - (10/17/23)
- Adherence to Antiretroviral Therapy and Its Effect
on Quality of Life among Persons with HIV in
the United States using Real-World Data - (10/17/23)
- The Performance of a Multidimensional Frailty Index in Comparison to the Frailty Phenotype to Assess Frailty in an Urban HIV clinic......"most PLWH at clinic were pre-frail or frail" - (10/17/23)
-
Impact of Polypharmacy on Gait Speed and Recurrent Falls in Older People Living with HIV. - (10/17/23)
- Association between integrase inhibitor plasma
concentrations and body weight gain in women living with HIV - (10/17/23)
- GLP-1 RECEPTOR AGONISTS PROMOTE WEIGHT LOSS AMONG PEOPLE WITH HIV - (10/17/23)
-
Clinical Outcome of People Living with HIV and Cirrhosis: A Clinical Cohort Study - (10/17/23)
-
A Prospective, Randomized Trial to Assess a
Protease Inhibitor-based Regimen Switch Strategy
to Manage Integrase Inhibitor-related Weight Gain: Post Hoc - (10/17/23)
- Weight Loss or Gain Predictors Hard to
Find in INSTI-to-PI Switch Trial - Mark Mascolini
(10/17/23)
- GLP-1 receptor agonists promote weight
loss among people with HIV
- Mark Mascolini (10/17/23)
-
Effects of Semaglutide on Adipose Tissue in HIV-Associated Lipohypertrophy - (10/17/23)
-
Predicted uptake of novel HIV treatment options in the United States - (10/17/23)
- Predicted uptake of novel HIV treatment options in the United States - (10/16/23)
- Tesamorelin reduces visceral tissue and liver fat in INSTI-treated persons with HIV - Mark Mascolini (10/16/23)
- Factors driving decisions in the use of HIV Pre-Exposure
Prophylaxis: Data from a real-world study in the United States
- (10/16/23)
- Increase in New HIV Diagnoses Following Decrease
in Use of Pre-exposure Prophylaxis (PrEP) During the COVID-19 Pandemic - (10/16/23)
- The Real-World Impact of Pre-Exposure Prophylaxis (PrEP) Prescription
Uptake and Dispensing Status on HIV Infection Risk in the US - (10/16/23)
- Evaluating Pre-Exposure Prophylaxis Use in a Large Integrated Rural US Health System - (10/16/23)
- Facilitators and Barriers to Engaging in PrEP and
Gender Affirming Therapy for Black and Latina
Transgender Women in South Florida - (10/16/23)
- A Quality Improvement Initiative for HIV Prevention in Underserved Communities - (10/16/23)
- Black Race, Perceived Stress Affect CVD Risk Conditions in PLHIV - (10/16/23)
- Efficacy, safety and tolerability of switching to dolutegravir/lamivudine in virologically suppressed adults living with HIV on bictegravir/emtricitabine/tenofovir alafenamide -the DYAD study - (10/16/23)
- Virological Suppression in People With HIV-1 (PWH) Receiving Dolutegravir/Lamivudine Was High and Similar Across Age Groups Despite Older PWH Having Increased Rates of Comorbidities and Polypharmacy (TANDEM Subgroup Analysis) - (10/16/23)
-
Dolutegravir/Rilpivirine STR Switch in Persons with
HIV-1 and Chronic Kidney Disease: 48 Wk Results - (10/16/23)
- SOLAR 12-Month North American Results:
Randomized Switch Trial of CAB + RPV LA vs. Oral BIC/FTC/TAF - (10/16/23)
- Clinical Outcomes at Month 6 After Initiation of Cabotegravir and Rilpivirine Long-Acting (CAB+RPV LA) in an Observational Real-World Study (BEYOND) - (10/16/23)
- Durable Efficacy and Robust CD4+ T-cell Count Improvement Observed Across Age, Race, Sex, and Geographic Subgroups of Heavily Treatment-Experienced People With Multidrug-Resistant HIV-1 After 240 Weeks of Fostemsavir Treatment - (10/16/23)
- Perspectives of People With HIV 6 Months Following a Switch to Cabotegravir and Rilpivirine Long-Acting (CAB+RPV LA) in an Observational Real-World US Study (BEYOND) - (10/16/23)
- Risk Factors, Risk Perception, and Long-Acting
PrEP Awareness and Interest Among US Women:
A National Survey
- (10/16/23)
-
Exploring Cisgender Women's HIV Pre-Exposure Prophylaxis (PrEP) Needs and Preferences Across Settings: the Role of Social-Structural Factors - (10/16/23)
- Integrating Long-Acting Injectable Cabotegravir for PrEP Into Standard of Care for Cisgender Women, Transgender Women, Transgender Men, and Men Who Have Sex With Men: Results From the PILLAR & EBONI Studies - (10/16/23)
- Engaging Black Women on Cabotegravir LA for PrEP by Optimizing Novel Implementation Strategies (EBONI) Study: Provider Perceptions of Appropriateness of Cabotegravir LA for PrEP for Cis-and-Trans Black Women - (10/16/23)
- Healthcare Staff Perceptions of Feasibility and Acceptability on Implementing Injectable HIV Pre-exposure Prophylaxis Into Standard of Care: Baseline Results From the PrEP Implementation Study for Cabotegravir Long Acting for Men in the Real World (PILLAR) - (10/16/23)
- Steady-state PK of Fixed Dose Dolutegravir-Rilpivirine in Hemodialysis - (10/16/23)
-
Randomized-controlled trial evaluating the outcome between switching to tenofovir disoproxil fumarate(TDF)/lamivudine(3TC)/dolutegravir(DTG) versus maintaining the current NNRTI or boosted-PI-containing regimen in PLWH in Thailand - a pilot study from single center
- (10/16/23)
- Impact of Dolutegravir-based Regimen on Metabolic Syndrome and its Components in Adults living with HIV in Care at Hospital Roosevelt in Guatemala City - (10/16/23)
- Stopping ARVs Tied to Weight Loss (EFV and TDF) Boosts Odds of Weight Gain on Integrase Drugs
- Mark Mascolini (10/16/23)
- Viral Blips While on Antiretroviral Therapy are Associated with Virologic Failure
- (10/16/23)
- Suppressed switch to bictegravir/emtricitabine/tenofovir
alafenamide vs dolutegravir/lamivudine
DTG/3TC Stopped More Than B/F/TAF After Switch From Suppressive Regimen
- Mark Mascolini (10/16/23)
- Hepatitis B Reactivation in Persons with HIV with
Positive Hepatitis B Core Antibody after Switching to
Antiretroviral Therapy without Hepatitis B Activity - (10/13/23)
-
HIV Following Oral Pre-Exposure Prophylaxis (PrEP) Initiation - (10/13/23)
-
Acceptability of an HIV Pre-Exposure Prophylaxis (PrEP)
Shared Decision-Making Tool (SDT) for Diverse Populations and Healthcare Providers - (10/13/23)
- Real-World Use of Long-Acting Cabotegravir + Rilpivirine in People with HIV with Detectable Viral Loads at Initiation: Findings from the OPERAŽ Cohort - (10/13/23)
- Over 80% With Detectable HIV Load Respond to CAB + RPV LA - Mark Mascolini (10/13/23)
-
At-Home vs. In-Clinic Receipt of Cabotegravir and
Rilpivirine Long-Acting: An Implemtentation Science Trial - (10/13/23)
- Real-World Adherence and Persistence with Cabotegravir + Rilpivirine Long Acting (CAB + RPV LA) compared with Oral ART among PWH in the US: The ABOVE Study - (10/13/23)
-
Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide
(B/F/TAF) Versus Dolutegravir (DTG)-Based 3-Drug Regimens in
Adults With HIV Who Have Suboptimal Antiretroviral Adherence
- (10/13/23)
- Real-World Effectiveness and Tolerability of
Bictegravir/Emtricitabine/Tenofovir Alafenamide
(B/F/TAF) in Treatment-Experienced People With HIV
and a History of Antiretroviral Drug Resistance Mutations
- (10/13/23)
-
Creating HCV Care Cascades in HIV Clinics in Real Time - (10/11/23)
- Hepatitis C Virus infection and cure by priority
population among New York City Ryan White HIV/AIDS Program Part A - (10/11/23)
- Massachusetts HCV Treatment Report Card:
Hepatitis C Virus Care Cascade for Females
of Reproductive Age with Opioid Use Disorder, 2014-2021 - (10/11/23)
- Hepatitis C Virus Among Inpatients in the Direct-acting
Antiviral Era: Prevalence, Linkage to Care, Treatment
Disparities, and Comorbidity Burden - (10/11/23)
- Trends in viral hepatitis and hepatocellular carcinoma in New York City, 2001-2018 - (10/11/23)
- An Analysis of Social Determinants of Health and
their Implications for Hepatitis C Virus Treatment
in People Who Inject Drugs: The Case of Baltimore. - (10/11/23)
- Anti-HCV Therapy Starts Faster, Finishes More Often With Community Pharmacy Than Medicaid Mail-Order System - Mark Mascolini (10/11/23)
-
IMPACT OF AN INNOVATIVE COMMUNITY BASED
CONTRACTED PHARMACY ON HCV ELIMINATION IN NEW JERSEY, USA - (10/11/23)
- Efficacy and Safety of Long-Acting Subcutaneous Lenacapavir in Heavily Treatment-Experienced People with Multi-Drug Resistant HIV: Week 104 Results - (10/11/23)
- Weight and Metabolic Changes with Long-Acting Lenacapavir in a Combination Regimen in Treatment-Naïve People with HIV-1 at Week 80 - (10/11/23)
- Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) Versus Dolutegravir (DTG)-Based 3-Drug Regimens in Adults With HIV Who Have Suboptimal Antiretroviral Adherence - (10/11/23)
- Impact of Subcutaneous Administration Sites on
the Clinical Pharmacokinetics of Lenacapavir, a
Long-Acting HIV Capsid Inhibitor: Does Body Site Matter? - (10/11/23)
- Each Added Comorbidity Cuts 4 Points Off QOL Index in US Women With HIV - Mark Mascolini (10/11/23)
- Only Half of MSM With HIV Getting Screened for Anal Cancer - Mark Mascolini (10/11/23)
- Efficacy, safety and tolerability of switching to dolutegravir/lamivudine in virologically suppressed adults living with HIV on bictegravir/emtricitabine/tenofovir alafenamide -the DYAD study - (10/11/23)
- Virological Suppression in People With HIV-1 (PWH) Receiving Dolutegravir/Lamivudine Was High and Similar Across Age Groups Despite Older PWH Having Increased Rates of Comorbidities and Polypharmacy (TANDEM Subgroup Analysis) - (10/11/23)
- Dolutegravir/Rilpivirine STR Switch in Persons with HIV-1 and Chronic Kidney Disease: 48 Wk Results - (10/11/23)
|
|
| |
|
|
|
|
|
|
